Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Copper tripeptide for Sale > kl80 Dulaglutide Retatrutide| china warehouse
kl80 Dulaglutide Retatrutide| china warehouse buy - large image1
kl80 Dulaglutide Retatrutide| china warehouse buy - image1
kl80 Dulaglutide Retatrutide| china warehouse buy - image2
kl80 Dulaglutide Retatrutide| china warehouse buy - image3
kl80 Dulaglutide Retatrutide| china warehouse buy - image4
kl80 Dulaglutide Retatrutide| china warehouse buy - image5
kl80 Dulaglutide Retatrutide| china warehouse buy - image6

kl80 Dulaglutide Retatrutide| china warehouse

COA 68 Inquiries

Unit Price: Get Latest Price
CAS No.:

89030-95-5

Grade:

Industrial Grade

Content:

80%

Port:

广东

Brand:

dcvpeptides

Packaging:

80mg*10 vials

Price valid (until):

2026-06-28

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
3 days
Qualification:
Main Products:

Peptides,Retatrutide,GHK-CU

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


    • High-purity lyophilized peptide powder with excellent stability
    • White or off-white appearance with clean and uniform texture
    • Carefully sealed vial for secure storage and transportation
    • Manufactured under strict quality control standards
    • Reliable consistency and convenient handling
    • Suitable for laboratory and research applications

    Sales Manager:Lucy        Whatsapp:+852 7012 4146        Email: yuluzhang105@gm ail.com


    ECHEMI Editorial Reference
    Copper Tripeptide is a tripeptide molecule rich in copper ions. Its sequence is GHK and it is widely present in human blood, saliva and urine. With age, the concentration of GHK gradually decreases, which is related to the decline of organ regeneration ability. Copper Tripeptide has strong antioxidant capacity, neutralizes free radicals, protects the skin from environmental damage, and with its unique copper ion affinity, it plays a role in promoting wound healing and activating skin regeneration.
    Copper tripeptide, also known as [N2-(N-Glycyl-L-histidyl)-L-lysinato(2-)]copper or GHK-Cu, is a naturally occurring tripeptide. It was first isolated from human plasma but can be found in saliva and urine. During wound healing, it may be freed from existing extracellular proteins via proteolysis. Studies have shown that GHK-Cu has a maximal biological effect at 10-9mol/L and Its concentration in the body decreases with age[1].

    Certificates

    Basic Info
    Product Name:

    Copper tripeptide

    Other Name:

    [N2-(N-Glycyl-L-histidyl)-L-lysinato(2-)]copper;Ghk-Cu/AHK-CU;Copper tripeptide (GHK-Cu);Prezatide copper,[N2-(N-Glycyl-L-histidyl)-L-lysinato(2-)]copper;tripeptide/GHK-Cu;Copper peptide, GHK-Cu, Copper tripeptide-1;GHK Copper;GHK.CU.HAC

    CAS No.:

    89030-95-5

    Molecular Formula:

    C14H21CuN6O4

    InChIKeys:

    DDNUEECOCUBKBT-MIIMWFGWNA-L

    Molecular Weight:

    400.91

    Exact Mass:

    402.10800

    EC Number:

    1308068-626-2

    Color/Form:

    Light blue to blue

    Characteristics
    PSA:

    186.03000

    XLogP3:

    1.04530

    Critical Temperature & Pressure:

    under inert gas (nitrogen or Argon) at 2–8 °C

    Research
    Class:

    GLP-1 receptor agonist (GLP-1 analog fused to human IgG4-Fc, long-acting)

    Status:

    FDA-approved (Trulicity 2014)

    Mechanism:

    A long-acting GLP-1 receptor agonist consisting of a modified human GLP-1 molecule (7-37) covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. The Fc fusion extends the half-life to ~5 days. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying.

    Activity note:

    Dulaglutide is a dual-agonist with GLP-1R activation. The exact EC50 is proprietary; functional potency is comparable to other long-acting GLP-1R agonists.

    Source:

    DrugBank: DB09095; PubChem CID 16135271.

    Clinical Development:

    NCT01394952; NCT01391252

    FDA:

    Trulicity (approved 2014-09-18)

    References
    DrugBank:

    DB09095

    PubChem:

    PubChem

    Disclaimer:

    Dulaglutide is FDA-approved as a prescription medicine (Trulicity) for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

    Hazard Identification

    Classification of the substance or mixture

    no data available

    GHS label elements, including precautionary statements

    Pictogram(s) no data available
    Signal word

    no data available

    Hazard statement(s)

    no data available

    Precautionary statement(s)
    Prevention

    no data available

    Response

    no data available

    Storage

    no data available

    Disposal

    no data available

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides,Retatrutide,GHK-CU

    Location:

    Room 503, 5th Floor, Office Unit 501, New Triumphal Arch Health Products Mall, Changzheng Road, Chengguan Town, Taihe County, Fuyang City, Anhui Province

    Payment Terms:

    TT against copy of documents,D/P,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    3 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    51-100

    Year of Establishment:

    2026

  • Inquiry History
    68 Inquiries
    Country Product Purchase Quantity Date Posted
    Australia

    Copper tripeptide

    10 PCS Oct 18, 2026
    United States

    Copper tripeptide

    10 MG Oct 11, 2026
    Bolivia

    Copper tripeptide

    10 PCS Oct 10, 2026
    France

    Copper tripeptide

    10 MT Sep 21, 2026
    Spain

    Copper tripeptide

    500  Sep 19, 2026
    Canada

    ghk cu

    1 G Sep 17, 2026
    United States

    Klow

    1 MG Sep 2, 2026
    Australia

    GHK-CU 89030-95-5| Pharmaceutical Grade for Drug Development and Research

    1 G Aug 15, 2026
    Germany

    GHK-Cu

    10 MG Aug 12, 2026
    United States

    GHK-Cu

    20 MG Aug 12, 2026
    United States

    GhkCu

    5 G Aug 5, 2026
    Thailand

    Copper Tripeptide-1

    2 G Aug 3, 2026
    United States

    GHK-Cu

    30 MG Aug 3, 2026
    United States

    ghkcu

    10 MG Jul 29, 2026
    Philippines

    Ghkcu

    20  Jul 28, 2026
    Philippines

    GHK CU+KPV

    10 PCS Jul 19, 2026
    United States

    Copper Tripeptide

    10 MG Jul 14, 2026
    United States

    ghk cu

    10 MG Jul 13, 2026
    United States

    Ghk cu

    12  Jul 8, 2026
    United States

    Ghk cu

    50 MG Jul 7, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.